NEW YORK, NY - November 21, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the publication of an abstract on ZIO-201, a stabilized form of isophosphoramide mustard (IPM). The preclinical abstract is published and available online in Blood, the official journal of the American Society of Hematology.

In abstract 4727 tit...  

PHILADELPHIA, PA - November 18, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that preclinical data for ZIO-102, an organic arsenic derivative, was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA. The abstract titled "Mechanisms of increased reactive oxy...  

NEW YORK, NY - October 31, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Monday, November 7, 2005 at 8:40 a.m. EST at The New York Palace Hotel in New York, NY. Dr. Lewis will provide an overview ...  

NEW YORK, NY - October 19, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announ ced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the C.E. Unterberg, Towbin Life Sciences Conference on Wednesday, October 26, 2005 a t 4:00 p.m. EST at The New York Palace Hotel in New York, NY. Dr. Lewis will pro vide an overview of th...  

New York, NY - September 26, 2005 - ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today its ticker symbol has changed from "ESWB" to "ZIOP". The symbol change, which is effective as of the opening of business today, is a result of the Company's previously announced merger with ZIOPHARM, Inc. In connection with the merger, the combined comp...  

CHARLESTOWN, MA June 6, 2005 - ZIOPHARM, Inc. announced today that it had completed its Series A Convertible Preferred Stock offering. Paramount BioCapital, Inc. served as the lead placement agent and gross proceeds were approximately $18.1 million. The net proceeds from the Offering will be used for research and development, licensing fees a...  

CHARLESTOWN, MA May 19, 2005 - ZIOPHARM, Inc. announced dosing of the first patient in its phase I study of the safety and dosing of ZIO-101, the Company's proprietary small molecule organic arsenic. The study, in up to 40 patients with diverse blood and bone marrow cancers, started on schedule just nine months after the Company licensed ZIO-...  

NEW HAVEN, CT April 5, 2005 - ZIOPHARM, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug Application (IND) for the clinical development of its proprietary organic arsenic compound, ZIO-101. The Company plans to initiate a dose-ranging Phase I trial of ZIO-101 in patients with hema...